Tiziana Life Sciences PLC TLSA to Present at the Q3 Virtual Investor Summit
16 Août 2021 - 7:11PM
RNS Non-Regulatory
TIDMTILS
Tiziana Life Sciences PLC
16 August 2021
Tiziana Life Sciences plc Invites You to Join Us at the Q3
Virtual Investor Summit
NEW YORK & LONDON, August 16, 2021 - Tiziana Life Sciences
plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company"), a
biotechnology company focused on innovative therapeutics for
oncology, neurology, inflammation and infectious diseases,
announces today that Dr. Kunwar Shailubhai, CEO & CSO will be
attending the Q3 Virtual Investor Summit.
Event Q3 Investor Summit
Date August 17-18th, 2021
-----------------------------------------------------------
Presentation August 18th at 3.30pm ET
-----------------------------------------------------------
Location https://zoom.us/webinar/register/WN_Az9VTw1QRr6aESxsPWSloQ
-----------------------------------------------------------
About Tiziana Life Sciences plc
Tiziana Life Sciences plc (NASDAQ: TLSA) (LSE: TILS) is a UK
biotechnology company that focuses on the discovery and development
of novel molecules to treat human disease in oncology and
immunology. In addition to Milciclib (a CDK inhibitor being
developed in oncology), the Company is also developing Foralumab in
COVID-19, multiple sclerosis, and Crohns Disease. Foralumab is the
only second generation fully human anti-CD3 monoclonal antibody in
clinical development in the world. This Phase 2 compound has
potential application in a wide range of autoimmune and
inflammatory diseases, such as nonalcoholic steatohepatitis (NASH),
ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D),
Crohn's disease, psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The Company is
accelerating development of anti-Interleukin 6 receptor (IL6R) mAb,
a fully human monoclonal antibody for treatment of IL6-induced
inflammatory pulmonary diseases.
For further information:
Tiziana Life Sciences plc
Kunwar Shailubhai
02074952379
info@tizianalifesciences.com
About the Investor Summit
The Investor Summit is an exclusive, independent conference
dedicated to connecting smallcap and microcap companies with
qualified investors. The Q3 Investor Summit will take place
virtually, featuring 80+ companies and over 800 investors,
consisting of institutional investors, family offices, and private
wealth.
To request complimentary investor registration: please click
here: Complimentary Investor Registration
Contact:
Sasha Murray at sasha@investorsummitgroup.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAXPKFENFEFA
(END) Dow Jones Newswires
August 16, 2021 13:11 ET (17:11 GMT)
Tiziana Life Sciences (LSE:TILS)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Tiziana Life Sciences (LSE:TILS)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024